Repositioning Candidate Details
| Candidate ID: | R0366 |
| Source ID: | DB01009 |
| Source Type: | approved; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Ketoprofen |
| Synonyms: | 2-(3-Benzoylphenyl)propionic acid; 3-Benzoyl-alpha-methylbenzeneacetic acid; 3-Benzoyl-α-methylbenzeneacetic acid; 3-Benzoylhydratropic acid; Ketoprofen; m-Benzoylhydratropic acid |
| Molecular Formula: | C16H14O3 |
| SMILES: | CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. |
| CAS Number: | 22071-15-4 |
| Molecular Weight: | 254.2806 |
| DrugBank Indication: | For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain. |
| DrugBank Pharmacology: | Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain. |
| DrugBank MoA: | The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. |
| Targets: | Prostaglandin G/H synthase 1 inhibitor; Prostaglandin G/H synthase 2 inhibitor; C-X-C chemokine receptor type 1 other |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |